Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis

British Journal of Rheumatology

Volumn 36, Issue 12, 1997, Pages 1276-1282

  Aringer, M ^a   Graninger, W B ^a   Smolen, J S ^a   Kiener, H P ^a   Steiner, C W ^a   Trautinger, F ^b   Knobler, R ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; bcl 2; CD95; fas; Lymphocytes; Photopheresis; Systemic sclerosis

Indexed keywords

CD4 ANTIGEN; FAS ANTIGEN; PROTEIN BCL 2;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOCYTE CULTURE; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUVA; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIGENS, CD95; APOPTOSIS; CELLS, CULTURED; FEMALE; HUMANS; LYMPHOCYTE SUBSETS; LYMPHOCYTES; MALE; MIDDLE AGED; PHOTOPHERESIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SCLERODERMA, SYSTEMIC;

EID: 0031441124     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Kahari VM. Activation of dermal connective tissue in scleroderma. Ann Med 1993;25:511-8.
2. Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996;35:1122-6.
3. Kovalchik MT, Guggenheim SJ, Silverman MH, Robertson JS, Steigerwald JC. The kidney in progressive systemic sclerosis: a prospective study. Ann Intern Med 1978;89:881-7.
4. Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403-13.
5. Postlethwaite AE. Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol 1995;12:247-58.
6. Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991;18:1496-503.
7. Gisslinger H, Burghuber OC, Stacher G et al. Efficacy of cyclosporin A in systemic sclerosis. Clin Exp Rheumatol 1991;9:383-90.
8. Zachariae H, Halkier Sorensen L, Heickendorff L, Zachariae E, Hansen HE. Cyclosporin A treatment of systemic sclerosis. Br J Dermatol 1990;122:677-81.
9. Fuchs D, Fruchter L, Fishel B, Holtzman M, Yaron M. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol 1986;5:527-30.
10. Sharada B, Kumar A, Kakker R et al. Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. Rheumatol Int 1994;14:91-4.
11. Beckett VL, Conn DL, Fuster V et al. Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 1984;27:1137-43.
12. Humbert P, Dupond JL, Agache P et al. Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Dermatol Venereol 1993;73:449-51.
13. Edelson RL. Photopheresis: a clinically relevant immunobiologic response modifier. Ann NY Acad Sci 1991;636:154-64.
14. Knobler RM, Graninger W, Lindmaier A, Trautinger F, Smolen JS. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. Arthritis Rheum 1992;35:319-24.
15. Malawista SE, Trock DH, Edelson RL. Treatment of rheumatoid arthritis by extracorporeal photochemotherapy. A pilot study. Arthritis Rheum 1991;34:646-54.
16. Wilfert H, Honigsmann H, Steiner G, Smolen J, Wolff K. Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol 1990;122:225-32.
17. Di Spaltro FX, Cottrill C, Cahill C et al. Extracorporeal photochemotherapy in progressive systemic sclerosis. Int J Dermatol 1993;32:417-21.
18. Rook AH, Freundlich B, Jegasothy BV et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol 1992;128:337-46.
19. Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: Relevance to mechanism of therapeutic action. J Invest Dermatol 1996;107:235-42.
20. Williams GT. Role of apoptosis in the immune system. Biochem Cell Biol 1994;72:447-50.
21. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM. Regulation of apoptosis in the immune system. Curr Opin Immunol 1994;6:279-89.
22. Linette GP, Korsmeyer SJ. Differentiation and cell death: lessons from the immune system. Curr Opin Cell Biol 1994;6:809-15.
23. McDonnel TJ, Korsmeyer SJ. Progression from hyperplasia to high-grade malignant lymphopma in mice transgenic for the t (14;18). Nature 1991;349:254-6.
24. Mountz JD, Edwards CK III. Murine models of autoimmune disease. Curr Opin Rheumatol 1992;4:621-9.
25. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
26. Watson ML, Rao JK, Gilkeson GS et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992;176:1645-56.
27. Lynch DH, Watson ML, Alderson MR et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994;1:131-6.
28. Su X, Zhou T, Yang PA, Wang Z, Mountz JD. Hematopoietic cell protein-tyrosine phosphatase-deficient motheaten mice exhibit T cell apoptosis defect. J Immunol 1996;156:4198-208.
29. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23: 581-90.
30. Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987;316:297-303.
31. Heald PW. Reply. J Am Acad Dermatol 1993;28: 1023-4.
32. Aringer M, Wintersberger W, Steiner CW et al. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:1423-30.
33. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
34. Sgonc R, Boeck G, Dietrich H, Gruber J, Recheis H, Wick G. Simultaneous determination of cell surface antigens and apoptosis. Trends Genet 1994;10:41-2.
35. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994;152:3685-92.
36. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K Jr. Soluble and cellular markers of immune activation in patients with systemic sclerosis. Clin Immunol Immunopathol 1990;56:259-70.
37. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53.
38. Debatin KM, Goldmann CK, Bamford R, Waldmann TA, Krammer PH. Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. Lancet 1990;335:497-500.
39. Matsubara K, Kubota M, Adachi S et al. Induction of apoptosis in childhood acute leukemia by chemotherapeutic agents: failure to detect evidence of apoptosis in vivo. Eur J Haematol 1994;52:47-52.
40. Falasca L, Bergamini A, Serafino A, Balabaud C, Dini L. Human Kupffer cell recognition and phagocytosis of apoptotic peripheral blood lymphocytes. Exp Cell Res 1996;224:152-62.
41. Yoshino T, Kondo E, Cao L et al. Inverse expression of bcl-2 protein and Fas antigen in lymphoblasts in peripheral lymph nodes and activated peripheral blood T and B lymphocytes. Blood 1994;83:1856-61.
42. Iwai K, Miyawaki T, Takizawa T et al. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994;84:1201-8.
43. Boudet F, Lecoeur H, Gougeon ML. Apoptosis associated with ex vivo down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic CD8+ T lymphocytes during HIV infection. J Immunol 1996;156:2282-93.
44. Ohsako S, Hara M. Harigai M, Fukasawa C, Kashiwazaki S. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994;73: 109-14.
45. Ogawa N, Dang H, Kong L, Anya JM, Liu GT, Takal N. Lymphocyte apoptosis and apoptosis-associated gene expression in Sjögrens syndrome. Arthritis Rheum 1996;39:1875-85.
46. Mysler E, Bini P, Drappa J et al. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994;93:1029-34.
47. Siegel RM, Katsumata M, Miyashita T, Louie DC, Greene MI, Reed JC. Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc Natl Acad Sci USA 1992;89:7003-7.
48. Conroy LA, Alexander DR. The role of intracellular signalling pathways regulating thymocyte and leukemic T cell apoptosis. Leukemia 1996;10:1422-35.
49. Moreno MB, Memon SA, Zacharchuk CM. Apoptosis signaling pathways in normal T cells: differential activity of Bcl-2 and IL-1beta-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity. J Immunol 1996;157: 3845-9.
50. Gombert W, Borthwick NJ, Wallace DL et al. Fibroblasts prevent apoptosis of IL-2-deprived T cells without inducing proliferation: a selective effect on Bcl-XL expression. Immunology 1996;89:397-404.
51. Lin RH, Hwang YW, Yang BC, Lin CS. TNF receptor-2-triggered apoptosis is associated with the down-regulation of Bcl-xL on activated T cells and can be prevented by CD28 costimulation. J Immunol 1997;158:598-603.
52. Fournel S, Genestier L, Robinet E, Flacher M, Revillard JP. Human T cells require IL-2 but not G1/S transition to acquire susceptibility to Fas-mediated apoptosis. J Immunol 1996;157:4309-15.